634 related articles for article (PubMed ID: 15812814)
21. Spatial diversity of blood-brain barrier alteration and macrophage invasion in experimental autoimmune encephalomyelitis: a comparative MRI study.
Ladewig G; Jestaedt L; Misselwitz B; Solymosi L; Toyka K; Bendszus M; Stoll G
Exp Neurol; 2009 Nov; 220(1):207-11. PubMed ID: 19733560
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of glial cell activation ameliorates the severity of experimental autoimmune encephalomyelitis.
Guo X; Nakamura K; Kohyama K; Harada C; Behanna HA; Watterson DM; Matsumoto Y; Harada T
Neurosci Res; 2007 Dec; 59(4):457-66. PubMed ID: 17920148
[TBL] [Abstract][Full Text] [Related]
23. The slow Wallerian degeneration gene, WldS, inhibits axonal spheroid pathology in gracile axonal dystrophy mice.
Mi W; Beirowski B; Gillingwater TH; Adalbert R; Wagner D; Grumme D; Osaka H; Conforti L; Arnhold S; Addicks K; Wada K; Ribchester RR; Coleman MP
Brain; 2005 Feb; 128(Pt 2):405-16. PubMed ID: 15644421
[TBL] [Abstract][Full Text] [Related]
24. Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss.
Butzkueven H; Emery B; Cipriani T; Marriott MP; Kilpatrick TJ
Glia; 2006 May; 53(7):696-703. PubMed ID: 16498619
[TBL] [Abstract][Full Text] [Related]
25. Steroid protection in the experimental autoimmune encephalomyelitis model of multiple sclerosis.
Garay L; Gonzalez Deniselle MC; Gierman L; Meyer M; Lima A; Roig P; De Nicola AF
Neuroimmunomodulation; 2008; 15(1):76-83. PubMed ID: 18667803
[TBL] [Abstract][Full Text] [Related]
26. T-cell-mediated disruption of the neuronal microtubule network: correlation with early reversible axonal dysfunction in acute experimental autoimmune encephalomyelitis.
Shriver LP; Dittel BN
Am J Pathol; 2006 Sep; 169(3):999-1011. PubMed ID: 16936273
[TBL] [Abstract][Full Text] [Related]
27. Relationship of acute axonal damage, Wallerian degeneration, and clinical disability in multiple sclerosis.
Singh S; Dallenga T; Winkler A; Roemer S; Maruschak B; Siebert H; Brück W; Stadelmann C
J Neuroinflammation; 2017 Mar; 14(1):57. PubMed ID: 28302146
[TBL] [Abstract][Full Text] [Related]
28. Neuropathic pain behaviours in a chronic-relapsing model of experimental autoimmune encephalomyelitis (EAE).
Olechowski CJ; Truong JJ; Kerr BJ
Pain; 2009 Jan; 141(1-2):156-64. PubMed ID: 19084337
[TBL] [Abstract][Full Text] [Related]
29. Neurodegeneration in autoimmune CNS inflammation.
Herz J; Zipp F; Siffrin V
Exp Neurol; 2010 Sep; 225(1):9-17. PubMed ID: 19961850
[TBL] [Abstract][Full Text] [Related]
30. Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis.
Noorbakhsh F; Tsutsui S; Vergnolle N; Boven LA; Shariat N; Vodjgani M; Warren KG; Andrade-Gordon P; Hollenberg MD; Power C
J Exp Med; 2006 Feb; 203(2):425-35. PubMed ID: 16476770
[TBL] [Abstract][Full Text] [Related]
31. Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis.
Brown DA; Sawchenko PE
J Comp Neurol; 2007 May; 502(2):236-60. PubMed ID: 17348011
[TBL] [Abstract][Full Text] [Related]
32. VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE.
Roscoe WA; Welsh ME; Carter DE; Karlik SJ
J Neuroimmunol; 2009 Apr; 209(1-2):6-15. PubMed ID: 19233483
[TBL] [Abstract][Full Text] [Related]
33. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions.
Kornek B; Storch MK; Weissert R; Wallstroem E; Stefferl A; Olsson T; Linington C; Schmidbauer M; Lassmann H
Am J Pathol; 2000 Jul; 157(1):267-76. PubMed ID: 10880396
[TBL] [Abstract][Full Text] [Related]
34. Axonal dystrophy as a consequence of long-term demyelination.
Raine CS; Cross AH
Lab Invest; 1989 May; 60(5):714-25. PubMed ID: 2716284
[TBL] [Abstract][Full Text] [Related]
35. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis.
Linker RA; Lee DH; Demir S; Wiese S; Kruse N; Siglienti I; Gerhardt E; Neumann H; Sendtner M; Lühder F; Gold R
Brain; 2010 Aug; 133(Pt 8):2248-63. PubMed ID: 20826430
[TBL] [Abstract][Full Text] [Related]
36. Differential changes in axonal conduction following CNS demyelination in two mouse models.
Bando Y; Takakusaki K; Ito S; Terayama R; Kashiwayanagi M; Yoshida S
Eur J Neurosci; 2008 Nov; 28(9):1731-42. PubMed ID: 18973589
[TBL] [Abstract][Full Text] [Related]
37. Calcium channel blockers ameliorate disease in a mouse model of multiple sclerosis.
Brand-Schieber E; Werner P
Exp Neurol; 2004 Sep; 189(1):5-9. PubMed ID: 15296830
[TBL] [Abstract][Full Text] [Related]
38. The pathology of MS: new insights and potential clinical applications.
Pittock SJ; Lucchinetti CF
Neurologist; 2007 Mar; 13(2):45-56. PubMed ID: 17351524
[TBL] [Abstract][Full Text] [Related]
39. Characterization of brain lesions in a mouse model of progressive multiple sclerosis.
Levy H; Assaf Y; Frenkel D
Exp Neurol; 2010 Nov; 226(1):148-58. PubMed ID: 20736006
[TBL] [Abstract][Full Text] [Related]
40. [Neuronal injury in multiple sclerosis].
Correale J; Meli F; Ysrraelit C
Medicina (B Aires); 2006; 66(5):472-85. PubMed ID: 17137182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
